Investigational drug · Phase 3
Navlimetostat
Also called: BMS-986504, MRTX1719
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
10
Any phase or sponsor naming "Navlimetostat"
First trial start
2025
Sep 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Navlimetostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Ductal Adenocarcinoma
- Metastatic Non-small Cell Lung Cancer With MTAP Deletion
- Solid Tumors
- Carcinoma, Non-Small-Cell Lung
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Navlimetostat" as an intervention, largest first.
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07063745 · 590 participants (planned) · Start Jan 2, 2026 · Primary completion Aug 12, 2031
Drug: BMS-986504; Pembrolizumab and 5 more · For: Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 321 sites in all
- A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)Pivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07076121 · 470 participants (planned) · Start Oct 23, 2025 · Primary completion May 3, 2029
Drug: Navlimetostat; Gemcitabine and 2 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Phoenix, Arizona; Tucson, Arizona; Springdale, Arkansas · 269 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07492680 · 254 participants (planned) · Start Jul 27, 2026 · Primary completion Aug 15, 2028
Drug: Navlimetostat; Daraxonrasib and 8 more · For: Solid Tumors
Sites: San Francisco, California; Aurora, Colorado; Atlanta, Georgia · 58 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06855771 · 182 participants (planned) · Start Sep 9, 2025 · Primary completion Dec 29, 2028
Drug: BMS-986504; Izalontamab Brengitecan · For: Carcinoma, Non-Small-Cell Lung
Sites: Anchorage, Alaska; Boston, Massachusetts; Detroit, Michigan · 67 sites in all
- A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy ParticipantsRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07800897 · 80 participants (planned) · Start Aug 31, 2026 · Primary completion Mar 25, 2027
Drug: Navlimetostat; Itraconazole and 3 more · For: Healthy Female Adults
Sites: Québec, Canada
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07544628 · 64 participants (planned) · Start Apr 27, 2026 · Primary completion Nov 2, 2026
Drug: Navlimetostat · For: Healthy Participants
Sites: Decatur, Georgia; Austin, Texas · 4 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07077434 · 32 participants (planned) · Start Oct 15, 2025 · Primary completion Jan 19, 2027
Drug: BMS-986504 · For: Advanced Solid Tumors
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 12 sites in all
- A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic CancerNot yet recruiting
Daniel Nussbaum, M.D.Academic, hospital or other
NCT07905131 · 18 participants (planned) · Start Jan 15, 2027 · Primary completion Jun 30, 2029
Drug: Navlimetostat; mFOLFIRINOX Treatment Regimen · For: Pancreatic Ductal Adenocarcinoma (PDAC)
Sites: Durham, North Carolina
- Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung CancerRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07579221 · 17 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 1, 2029
Drug: Navlimetostat; Pumitamig · For: Non-Small Cell Lung Cancer
Sites: Houston, Texas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07777133 · 6 participants (planned) · Start Sep 29, 2026 · Primary completion Dec 5, 2026
Drug: Navlimetostat; [14C]Navlimetostat · For: Healthy Female Participants
Sites: Madison, Wisconsin; Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer.
Fu R, Wang Y, Rehman I, et al. · Biomolecules 2026
- MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.
Aldea M, Lenahan SM, Locquet MA, et al. · Ann Oncol 2026
- Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer.
Fu R, Wang Y, Rehman I, et al. · bioRxiv 2026
- Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies.
Bevilacqua R, Gasperini P, Cantore T, et al. · NPJ Precis Oncol 2026
- MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.
Rodon J, Johnson ML, George B, et al. · Cancer Res 2026
- Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.
Ross JS, Thummalapalli R, Febres-Aldana CA, et al. · J Thorac Oncol 2026
Also in development for Pancreatic Ductal Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- IBI343Arcotatug TavatecanPhase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- ChiauranibCS2164Phase 33 trials
Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
- SBP-101ivospeminPhase 31 trial
Panbela Therapeutics, Inc. · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.